Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical ...(ICAL is the clinical development of BUPI...),Health

Date:9/26/2007

ICAL is the clinical development of BUPIVACAINE SURGICAL IMPLANT when applied topically for the management of painful chronic and acute wounds, including ulcers of various etiologies and burns. Patients with such wounds can suffer severe pain, especially when the dressing is changed. It is anticipated that CollaRx BUPIVACAINE TOPICAL will provide long- acting analgesia between dressing changes and significantly reduce pain at the time of dressing change. In addition to the analgesia provided by the bupivacaine, the fibrillar collagen matrix is also expected to provide supplementary wound healing benefits, ultimately leading to accelerated wound closure.

About CollaGUARD(TM)

CollaGUARD is comprised almost entirely of purified type-I collagen protein and is clinically indicated in the US for the management of pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, partial and full thickness wounds, and superficial injuries. Unlike alginates, hydrogels and hydrocolloids used in other categories of advanced wound care products, collagen is a fully biodegradable and bioactive material with a pharmacological action that stimulates the natural wound healing process. In addition, CollaGUARD provides the barrier protection and transparency of film dressings, which allows the clinician to visually inspect and monitor the wound without removal.

About Innocoll, Inc.

Innocoll is a privately held, specialty pharmaceutical company focused on surgical and topical products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen- based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries and is entering phase 3 development in the US. In 2005, Innocoll acquired the worldwide marketing rights for this product from Essex Chemis AG, a
'/>"/>

SOURCE Innocoll, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer